15:28 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

FDA approves Agios' IDH1 inhibitor Tibsovo for AML

FDA approved Tibsovo ivosidenib (formerly AG-120) from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to treat relapsed or refractory acute myelogenous leukemia (AML) in adults with a susceptible isocitrate dehydrogenase 1 (IDH1) mutation. Tibsovo is the first FDA-approved...
16:44 , Jul 20, 2018 |  BC Extra  |  Company News

FDA approves Agios' IDH1 inhibitor for AML

FDA approved Tibsovo ivosidenib (formerly AG-120) from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) on Friday to treat relapsed or refractory acute myelogenous leukemia in adults with a susceptible isocitrate dehydrogenase 1 (IDH1) mutation. Tibsovo is the first...
17:33 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma Mouse studies suggest vaccines based on R123H-mutant IDH1 could help treat sarcomas harboring the mutation. In a syngeneic mouse model of sarcoma expressing the IDH1 R132H mutation, vaccination with a R132H-mutant IDH1 peptide decreased...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
15:00 , Jun 29, 2018 |  BC Week In Review  |  Company News

CStone gets Chinese rights to Agios' ivosidenib

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) gained exclusive rights from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to develop and commercialize ivosidenib (AG-120) in China, including Hong Kong and Macau, and Taiwan as monotherapy or in combination therapies. Agios...
20:18 , Jun 27, 2018 |  BC Extra  |  Company News

CStone gets Chinese rights to Agios' ivosidenib

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) gained exclusive rights from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to develop and commercialize ivosidenib (AG-120) in China, including Hong Kong and Macau, and Taiwan as monotherapy or in combination therapies. Agios...
15:33 , May 25, 2018 |  BC Week In Review  |  Clinical News

Agios reports Phase I safety data for IDH1/IDH2 inhibitor

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) reported safety data from 93 evaluable patients in a Phase I trial evaluating AG-881 to treat advanced solid tumors, including glioma, in patients with an isocitrate dehydrogenase 1 (IDH1) or IDH2...
23:54 , Apr 26, 2018 |  BC Innovations  |  Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
20:46 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Priority Review for Agios' ivosidenib

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said FDA accepted and granted Priority Review to an NDA for ivosidenib (AG-120) to treat relapsed or refractory acute myelogenous leukemia (AML) in patients with an isocitrate dehydrogenase 1 (IDH1) mutation....
19:45 , Feb 15, 2018 |  BC Extra  |  Company News

Priority Review for Agios' ivosidenib

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said FDA accepted and granted Priority Review to an NDA for ivosidenib (AG-120) to treat relapsed or refractory acute myelogenous leukemia (AML) in patients with an isocitrate dehydrogenase 1 (IDH1) mutation....